Quantitative application of the primary progressive aphasia consensus criteria
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To determine how well the consensus criteria could classify subjects with primary progressive aphasia (PPA) using a quantitative speech and language battery that matches the test descriptions provided by the consensus criteria.
Methods: A total of 105 participants with a neurodegenerative speech and language disorder were prospectively recruited and underwent neurologic, neuropsychological, and speech and language testing and MRI in this case-control study. Twenty-one participants with apraxia of speech without aphasia served as controls. Select tests from the speech and language battery were chosen for application of consensus criteria and cutoffs were employed to determine syndromic classification. Hierarchical cluster analysis was used to examine participants who could not be classified.
Results: Of the 84 participants, 58 (69%) could be classified as agrammatic (27%), semantic (7%), or logopenic (35%) variants of PPA. The remaining 31% of participants could not be classified. Of the unclassifiable participants, 2 clusters were identified. The speech and language profile of the first cluster resembled mild logopenic PPA and the second cluster semantic PPA. Gray matter patterns of loss of these 2 clusters of unclassified participants also resembled mild logopenic and semantic variants.
Conclusions: Quantitative application of consensus PPA criteria yields the 3 syndromic variants but leaves a large proportion unclassified. Therefore, the current consensus criteria need to be modified in order to improve sensitivity.
GLOSSARY
- agPPA=
- agrammatic variant of PPA;
- AOS=
- apraxia of speech;
- BNT=
- Boston Naming Test;
- DKEFS=
- Delis-Kaplan Executive Function System Card Sort;
- lvPPA=
- logopenic variant of PPA;
- MoCA=
- Montreal Cognitive Assessment battery;
- PPA=
- primary progressive aphasia;
- PPAOS=
- primary progressive apraxia of speech;
- PPTT=
- Pyramids and Palm Trees Test;
- Rey-O=
- Rey-Osterrieth Complex Figure Test;
- svPPA=
- semantic variant of PPA;
- WAB=
- Western Aphasia Battery–revised;
- WAB-AQ=
- Western Aphasia Battery–aphasia quotient
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 1108
Supplemental data at Neurology.org
- Received July 5, 2013.
- Accepted in final form November 19, 2013.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Views and Reviews
Classification of primary progressive aphasia and its variantsM.L. Gorno-Tempini, A.E. Hillis, S. Weintraub et al.Neurology, February 16, 2011 -
Article
Phonologic errors as a clinical marker of the logopenic variant of PPACristian E. Leyton, Kirrie J. Ballard, Olivier Piguet et al.Neurology, April 04, 2014 -
Article
Quantification of motor speech impairment and its anatomic basis in primary progressive aphasiaClaire Cordella, Megan Quimby, Alexandra Touroutoglou et al.Neurology, April 03, 2019 -
Research Article
Primary Progressive Aphasia Associated With GRN MutationsNew Insights Into the Nonamyloid Logopenic VariantDario Saracino, Sophie Ferrieux, Marie Noguès-Lassiaille et al.Neurology, May 12, 2021